Use of sugar derivatives for the prophylaxis and treatment of virus infections
AssigneeCiba-Geigy Corporation
InventorsBohumir Lukas, Karl H. S. Ruppin
Life of this patent
Estimating the term…
Abstract
Described are the use of hexopyranose compounds of the formula I ##STR1## for the prophylaxis and treatment of virus infections, and novel pharmaceutical preparations especially suitable for the use in accordance with the invention. The substituents in formula I have the meanings given in the claims.
Claims16
A pharmaceutical non-suppository composition for topical administration to a warm-blooded animal, said composition being in the form of an ointment, a cream, a paste, a gel, a foam, a spray, or a lipstick, said composition comprising a pharmaceutically acceptable carrier and an in-vivo antivirally effective amount, but not more than 0.9% by weight, of a pharmaceutically acceptable salt of N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-g lycero-3-hydroxyphosphoryloxy)-ethylamide, and said composition being free of an agent which is alone active as a vaccine.
A pharmaceutical composition for administration to a warm-blooded animal, said composition being in the form of a tablet, comprising between about 1 mg and about 10 mg of a pharmaceutically acceptable salt of N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-g lycero-3-hydroxyphosphoryloxy)-ethylamide together with at least 99% by weight of a pharmaceutically acceptable carrier, and said composition being free of an agent which is alone active as a vaccine.
A method of prophylaxis of a disease in a warm-blooded animal, said disease caused by a virus selected from viruses belonging to a family selected from Herpesviridae, Poxviridae, Picornavirideae, Orthomyxoviridae, and Paramyxoviridae, comprising administering to said warm-blooded animal in need thereof an in-vivo antivirally effective amount of a pharmaceutically acceptable salt of N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-g lycero-3-hydroxyphosphoryloxy)-ethylamide in the absence of a vaccine.
Dependencies are inferred from the claim text.